55576-67-5: Digoxin Inhouse Impurity G
Digoxin Inhouse Impurity G (CAS No.: 55576-67-5) or Neo-Digoxin is an adulteration of Digoxin which is a cardiac glycoside and a drug of choice for various heart diseases. Digoxin is extensively evaluated for rate control of atrial fibrillation (AF). However, it has been accompanied by increased mortality.
3β-[(2, 6-dideoxy-β-D-arabino-hexopyranosyl-(1→4)-2, 6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2, 6-dideoxy-β-D-ribo- hexopyranosyl)oxy]-12β, 14-dihydroxy-5β-card-20(22)-enolide
Lindenbaum, John, et al. “Inhibition of Digoxin Absorption by Neomycin.” Gastroenterology, vol. 71, no. 3, Sept. 1976, pp. 399–404, https://doi.org/10.1016/s0016-5085(76)80443-x.?Whitbeck, M. G., et al. “Increased Mortality among Patients Taking Digoxin–Analysis from the AFFIRM Study.” European Heart Journal, vol. 34, no. 20, Nov. 2012, pp. 1481–88, https://doi.org/10.1093/eurheartj/ehs348.?